EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Prevailing against Cost-Leader Competitors in the Pharmaceutical Industry

Gil Tomer

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector · 2008

DOI: 10.1057/jgm.2008.15 ↗
AbstractBibliografische Angaben

Abstract

Development of a new innovative drug is costly and risky, yet offers the company protection against competition and high returns on its investment. Years after, generic products are launched and the price of the drug sharply reduces. In recent years, research-based pharmaceutical companies have deployed a tactic, deployed in consumer products markets such as razors and disposable diapers, to deal with generic competition in shape of introduction of a line-extension product for its older drug. In many cases this newer version does not carry with it enough benefits, yet gives the company fresh monopolistic protection against competition. The widespread development of line-extension drugs is replacing the development of new chemical entities. Such a reduction in true innovation slows the stream of new medications flowing into the market. In addition, line-extension switching may force customers to change to newer, more expensive products and may prevent realisation of the cost saving introduced by the generic competitors. Owing to marked differences between pharmaceuticals and other products, line-extension switching may offer no or little benefit to customers, in comparison to older drugs. While low-risk levels and future revenues make new line-extension drugs lucrative to the company, they may not contribute any proportional social benefit to society.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →